Small Cap Feast

29th June 2023

Dish of the day
No Joiners today
Off the menu
No leavers today
 
Dish Of The Day:

Joiners: 
No joiners today.

Leavers: 
John Lewis of Hungerford Plc (JLH.L) has left AIM. 



What’s Cooking In The IPO Kitchen?

Ora Technology plc, a software company developing a digital carbon trading platform, offering users the ability to buy, sell and retire verified carbon credits in the voluntary carbon market, intends to join the AQSE Growth Market. Ora’s platform aims to allow access to carbon assets - and the broader carbon economy - with the goal of reducing the complexity of current industry practices, and an emphasis towards providing a simple and intuitive user experience.

Praetura Growth VCT plc, a newly established VCT announces its intention to float on the Main Market of the London Stock Exchange. The Company will provide growth funding to scalable businesses predominantly based in the North of England, across a range of sectors including technology and healthcare. The Company will be managed by Praetura Ventures Limited, a venture capital and EIS business associated with the wider Praetura Group, a Manchester based venture capital investor and small business lender. The Company is targeting to raise £10m at 1 pence per share, via an offer for subscription. The Directors will have the option to utilise an over-allotment facility that will allow the Company to issue a further 10m Ordinary Shares under the Offer.

CAB Payments Holdings Limited a market lender to business to business (B2B) cross-border payments and foreign exchange, specialising in emerging markets intends to join the Premium Segment of the Main Market. The Group announced revenues of £41.3m for the three months ended 31 March 2023 with the YTD adjusted EBITDA margin at 64%. The Offer is expected to comprise a secondary sell-down of existing ordinary shares by Merlin Midco Limited (a wholly owned subsidiary of Helios Investors III, L.P. and Helios Investors III (A), L.P.) It is rumoured to be valued at between £800m and £1bn with Admission currently expected to occur in July 2023.


Breakfast Buffet

AMTE Power 6.25p £2.3m (AMTE.L)
The UK developer and manufacturer of battery cells for specialist markets, announces that it now anticpates the UN certification of its Ultra High Power Cells in the third quarter of 2023. In the certification testing the Ultra High Power cell met all of the A-Sample target performance requirements; however, due to the identification of a minor manufacturing defect, the certification process of the cells has been halted. Cells from the next production batch, in the third quarter 2023, will now be used to certify the product.

Falanx Cyber Security 23p £1.2m (FCS.L)
The UK-based cyber security company provides a trading update for the year ended 31 March 2023 (FY23). Revenues for FY23 are expected to be c.£3.8m (2022: c.£3.5m) representing organic growth of c.9% year on year. The Group experienced steady growth on PenTest revenues at 5% and strong growth in SOC monitoring revenues, up c.21% from FY22. The business pipeline is healthy and the operating cost base has been reduced to improve financial performance.

Faron Pharmaceuticals OY 241p £153.2m (FARN.L)
The clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that it has conducted a placement of 2,601,510 newly issued treasury shares (Placing Shares) to raise EUR6.6m at an issue price of EUR2.55 per Placing share. The Issue Price represents a 11.8% discount to the close price on 28 June 2023. The fundraise will be used to accelerate its bexmarilimab development program, with a specific focus on combination trials in hematologic malignancies and to fund the working capital into Q4 2023.

Kibo Energy* 0.0575p £2.2m (KIBO.L)
The renewable energy-focused development company, releases its consolidated financial results for the year ended 31 December 2022. The consolidated results including MAST Energy show a total revenues of £1.04m (2021: £3.2k), operating loss of £10.57m (2021: £24.1m) and loss after tax of £10.9m (2021: £23.1m). The Group has a net debt position of £5.0m (2021: net debt of £404.5k). The Group has proceeded with the joint venture agreement to jointly develop a portfolio of Waste to Energy projects in South Africa with Industrial Green Energy Solutions (Pty) Ltd, which will initially develop a phased c. 8MW project for an industrial client, to be followed by six other projects at different sites, to a total generation of up to 50MW.

Physiomics* 0.98p £0.9m (PYC.L)
The oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions announces that following on from the company’s WRAP Retail Offer, an additional £25.4k was raised plus additional investor demand through the placing of £20k. This brings the total gross proceeds to £380.5k. The proceeds will be directed towards: further expansion and diversification of the client base; expansion of its consulting business into the adjacent area of pharmaceutical biostatistics services; and exploration of opportunities around its personalised oncology software offering.

Poolbeg Pharma* 8.85p £44.3m (POLB.L)
The clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, announces a significant breakthrough in its world first influenza Artificial Intelligence (AI) Programme with CytoReason. Poolbeg’s unique disease progression data from influenza human challenge trials combined with CytoReason’s broad repositories of curated disease data were analysed using CytoReason’s industry-leading AI-led platform. The analysis has led to the discovery of multiple novel drug targets for the treatment of influenza. Identification of drug targets from this unique data-set has previously been successful as p38 MAP Kinase, inhibited by POLB 001, identified as a driver of severe influenza but this required manual analysis that took several years. However, through the utilisation of CytoReason's cutting-edge AI technology, Poolbeg has now identified multiple novel drug targets in just 15 months.

REACT Group 1.35p £14.3m (REAT.L)
The specialist cleaning, hygiene and decontamination company announces its unaudited results for the six-month period ended 31 March 2023. Revenue increased by 82% to £9,320k (2022: £5,125k), as a result adjusted EBITDA up materially to £927k (2022: £162k) and gross margins up at 27% from 23%. Net debt increased to £257k (2022: £43k) an increase of nearly 500%. The Company has won multi year contracts worth £800k to provide services from all three segments of the business. It has further won a £500k 18-month contract with a Midlands based school alongside numerous contract renewals.

Roquefort Therapeutics* 6.75p £8.7m (ROQ.L)
The biotech company focused on developing first in class medicines in the high value and high growth oncology market, made the following statement prior to AGM today: Excellent progress across the portfolio, including further advancement of the in-house development of a platform of novel mRNA cancer medicines and the signing of a strategic license agreement with Randox Laboratories to utilise Midkine antibodies in medical diagnostics. The Company has made positive strides across their preclinical portfolio with its Midkine antibody programme targeting metastatic osteosarcoma which falls under the orphan drug category and carries significant commercial incentives. The in vitro results in the anti-cancer mRNA therapeutic in breast and liver cancer showed significant reduction in cancer growth and migration. The anti-cancer Midkine RNA programme produced >90% in vitro efficacy in human liver and neuroblastoma cancer cells. The Company is giving a presentation via the Investor Meet Platform at 11am on Wednesday 5 July 2023.

R&Q Insurance Holdings 44.9p £168.4m (RQIH.L)
The non-life global specialty insurance company focusing on the Program Management and Legacy Insurance businesses, announces its results for the year ended 31 December 2022. Group’s fee Income (excluding MGA stakes) was $92.0m (2021: $44.9m, a 105% increase). Pre-tax operating loss was $33.3m, impacted by $32.0m of adverse development and the transition to a fee-based revenue model at R&Q Legacy. During the year, the Group completed sale of minority stake in Tradesman Program Managers for $47m at 10x adjusted EBITDA and 3.7x initial investment and has raised $50m of preferred equity from Scopia Capital with the opportunity to raise an additional $10m to increase the capital resource of R&Q Legacy. The Group remains focused on the separation of R&Q Legacy and Accredited, with both showing strong pipelines.

Symphony Environmental Technologies* 7.5p £13.9m (SYM.L)
The specialists in technologies that make plastic and rubber products smarter, safer and more sustainable, provides the following update prior to its Annual General Meeting today at 10.30 am. Symphony's financial performance has sharply improved from 2022. As stated in the preliminary announcement on 30 May 2023, the Board expects Symphony to move back into profitability in the coming months, underpinned by the following: Middle East manufacturing and sales on plan; Administrative annual cost base now set 25% lower than 2022 levels; distribution costs as a proportion of revenues reduced by 50% due to generally lower shipping rates and efficiencies from the Middle East factory. Gross profit margins is expected to be at least 5% higher. The Company is confident in delivering positive updates throughout 2023.

29 June 2023
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced, or it is a rumour

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram